MACROGENICS INC — Form 8-K/A
Filed September 3, 2026 · analyzed by the 8-K Agent
8-K/A
▲ Likely positive
significance 72/100
What the filing says
MacroGenics completed the sale of its GMP manufacturing operations and CDMO business (located in Rockville, MD and Frederick, MD) to Bora Pharmaceuticals Co., Ltd. and Bora Biologics USA, LLC for $119.6M net cash (after $8.8M transaction costs), with up to $5M in contingent consideration tied to 2027–2028 manufacturing milestones. The transaction eliminates contract manufacturing revenue (~$52.6M in 2025; ~$14M in Q1 2026) and associated costs, representing a strategic exit from contract manufacturing to focus on pre-clinical and clinical-stage R&D.
Why this rating
For a $73.9M market-cap company, $119.6M gross proceeds is 162% of current market value—transformational capital injection. Eliminates loss-making CDMO line (~$36M manufacturing costs vs. $52.6M revenue in 2025). Increases cash 168% but also increases accumulated deficit adjustment. Material strategic refocus, not daily operations.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $4.25 ▲ 0.00% | at our read · unknown $4.25 | +10 min · unknown $4.25 ▲ 0.00% | +30 min · unknown $4.25 ▲ 0.00% | +1 hr · unknown $4.25 ▲ 0.00% | +4 hrs pending |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.